Question · Q3 2025
Skye requested more information on the expected revenue and EPS accretion from completed and progressing acquisitions for 2025 and 2026, along with key integration milestones and potential synergies.
Answer
Chairman and CEO Adam Schechter stated that acquisitions typically contribute 1.5% to 2.5% growth annually, consistent with Labcorp's long-term guidance, and the pipeline remains strong. He noted that hospital deals, when encompassing reference laboratory work, inpatient lab management, and outpatient lab acquisitions, generally result in margins similar to the company's average. Specific EPS accretion, integration milestones, or synergies for individual deals were not detailed.